Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SUCCESSFUL PREGNANCY IN AN INFERTILE WOMAN WITH A THYROTROPIN-SECRETING MACROADENOMA TREATED WITH SOMATOSTATIN ANALOG (OCTREOTIDE)
Autore:
CARON P; GERBEAU C; PRADAYROL L; SIMONETTA C; BAYARD F;
Indirizzi:
CHU RANGUEIL,SERV ENDOCRINOL,1 AVE J POLHES F-31054 TOULOUSE FRANCE CHU RANGUEIL,INSERM,U151 F-31054 TOULOUSE FRANCE LABS SANDOZ F-92500 RUEIL MALMAISON FRANCE
Titolo Testata:
The Journal of clinical endocrinology and metabolism
fascicolo: 3, volume: 81, anno: 1996,
pagine: 1164 - 1168
SICI:
0021-972X(1996)81:3<1164:SPIAIW>2.0.ZU;2-D
Fonte:
ISI
Lingua:
ENG
Soggetto:
PITUITARY-ADENOMAS; THYROID-FUNCTION; SMS-201-995; TUMORS; RECEPTORS; INVITRO; PATIENT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
26
Recensione:
Indirizzi per estratti:
Citazione:
P. Caron et al., "SUCCESSFUL PREGNANCY IN AN INFERTILE WOMAN WITH A THYROTROPIN-SECRETING MACROADENOMA TREATED WITH SOMATOSTATIN ANALOG (OCTREOTIDE)", The Journal of clinical endocrinology and metabolism, 81(3), 1996, pp. 1164-1168

Abstract

Somatostatin analogs are an alternative medical treatment in patientswith TSH-secreting pituitary adenoma. A 31-yr-old infertile woman with a TSH-secreting macroadenoma. was treated with continuous sc infusion of 300 mu g octreotide/day. After 3 months, euthyroid status was restored, and pituitary magnetic resonance imaging showed a reduction of the macroadenoma. Subsequently, the patient was found to be pregnant, and octreotide was stopped after 1 month of gestation. Serum TSH and free thyroid hormone concentrations returned to pretreatment values. At6 months of pregnancy, a visual field examination was abnormal, and amagnetic resonance imaging scan showed an enlargement of the pituitary adenoma. Reinstitution of octreotide treatment was associated with normalization of TSH and free thyroid hormone concentrations, a rapid improvement of visual fields, and a new reduction in the size of pituitary macroadenoma. Octreotide treatment was continued until an electivecesarean section was performed at 8 months gestation. Despite the presence of im -munoreactive octreotide in the umbilical cord, neonatal thyroid parameters were normal, and a physiological rise in TSH with the increase in thyroid hormone concentrations occurred in the neonate. In conclusion, 1) octreotide treatment is effective in controlling TSH-secreting macroadenoma during pregnancy; 2) despite the transplacental passage of immunoreactive octreotide, physiological changes in thyroid parameters occur in the neonate, and 3) exposure of the fetus to octreotide during the first month as well as the last trimester of gestation did not induce any malformation or affect fetal development.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 22:40:58